Comparative Pharmacology
Head-to-head clinical analysis: PREMPHASE PREMARIN CYCRIN 14 14 versus STILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREMPHASE PREMARIN CYCRIN 14 14 versus STILBESTROL.
PREMPHASE (PREMARIN;CYCRIN 14/14) vs STILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREMPHASE combines conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which regulate gene transcription and produce effects in tissues such as the endometrium, breast, and bone. Medroxyprogesterone acetate is a progestin that induces secretory changes in the endometrium and reduces the risk of endometrial hyperplasia associated with estrogen therapy.
Synthetic nonsteroidal estrogen that acts by binding to estrogen receptors (ERα and ERβ), leading to translocation to the nucleus, modulation of gene transcription, and promotion of estrogenic effects in target tissues.
One tablet daily (conjugated estrogens 0.625 mg/medroxyprogesterone acetate 5 mg) for 14 days, followed by one tablet daily (conjugated estrogens 0.625 mg) for 14 days; continuous cycling. Oral administration.
0.5 to 2 mg orally once daily; or 25 mg intramuscularly once daily for 5 days; for prostate cancer: 1 to 3 mg orally once daily.
None Documented
None Documented
Conjugated estrogens: terminal half-life 10–24 h (accumulation with daily dosing). MPA: terminal half-life 12–33 h (mean ∼17 h).
Terminal elimination half-life is approximately 24-48 hours, with a prolonged phase due to enterohepatic recirculation; requires dosing adjustment in hepatic impairment.
Conjugated estrogens and MPA are primarily excreted in urine (∼90% as glucuronide and sulfate conjugates) and feces (∼10% as unabsorbed drug and biliary metabolites).
Renal excretion of glucuronide and sulfate conjugates accounts for approximately 60-80% of an administered dose; biliary/fecal excretion accounts for 15-30%; less than 5% is excreted unchanged in urine.
Category C
Category C
Estrogen/Progestin Combination
Estrogen